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Abstract
Background: Despite the significant global loss of DNA hydroxymethylation marks in prostate cancer tissues, the
locus-specific role of hydroxymethylation in prostate tumorigenesis is unknown. We characterized
hydroxymethylation and methylation marks by performing whole-genome next-generation sequencing in
representative normal and prostate cancer-derived cell lines in order to determine functional pathways and key
genes regulated by these epigenomic modifications in cancer.
Results: Our cell line model shows disruption of hydroxymethylation distribution in cancer, with global loss and
highly specific gain in promoter and CpG island regions. Significantly, we observed locus-specific retention of
hydroxymethylation marks in specific intronic and intergenic regions which may play a novel role in the regulation
of gene expression in critical functional pathways, such as BARD1 signaling and steroid hormone receptor signaling
in cancer. We confirm a modest correlation of hydroxymethylation with expression in intragenic regions in prostate
cancer, while identifying an original role for intergenic hydroxymethylation in differentially expressed regulatory
pathways in cancer. We also demonstrate a successful strategy for the identification and validation of key candidate
genes from differentially regulated biological pathways in prostate cancer.
Conclusions: Our results indicate a distinct function for aberrant hydroxymethylation within each genomic feature
in cancer, suggesting a specific and complex role for the deregulation of hydroxymethylation in tumorigenesis,
similar to methylation. Subsequently, our characterization of key cellular pathways exhibiting dynamic enrichment
patterns for methylation and hydroxymethylation marks may allow us to identify differentially epigenetically
modified target genes implicated in prostate cancer tumorigenesis.
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Background
Tumorigenesis is regulated by a cascade of genetic and
epigenetic alterations, with aberrant cytosine base
methylation (5mC) acting as one of the key defining
characteristics of tumor cells. CpG islands (CGIs), char-
acterized by clusters composed of cytosine nucleotides
followed by guanines, are usually unmethylated in nor-
mal conditions. However, in cancer, locus-specific hyper-
methylation of CGIs, particularly in the promoter
regions of tumor suppressor genes, results in their loss
of expression [1–3]. Simultaneously, genome-wide global
hypomethylation of repetitive sequences in tumors re-
sults in genomic instability, promoting chromosomal re-
arrangement and the reactivation of transposable
elements [4, 5].
5-Hydroxymethylated marks (5hmC) were first charac-
terized in mammalian genomes as transient intermedi-
ates in the process of DNA demethylation [6]. However,
the recent discovery of 5hmC as a stable epigenetic mark
that also shows global loss in solid tumors and
hematological malignancies [7, 8] has opened up new av-
enues for investigation into the dynamics of epigenetic
regulation in cancer. 5hmC shows striking differences in
distribution patterns among human tissues, exhibiting
very high content in the brain and low content in the
blood, spleen, and placental tissue [9, 10]. Genomic
5hmC distribution also differs by region, showing en-
richment at exon-intron boundaries, exons, promoters,
and enhancer elements [11–14]. Generally, the presence
of 5hmC marks is associated with increased expression
[14, 15]; however, the role of promoter hydroxymethyla-
tion in regulating expression may differ based on cell
type [16].
Several pieces of evidence suggest a key role for 5hmC
in governing tumorigenesis. Firstly, the genome-wide
loss of 5hmC in cancer cannot be completely explained
by the corresponding global loss of 5mC, indicating an
independent role for 5hmC alterations in tumors [7].
Secondly, 5hmC correlates directly with differentiation
state in cells during development, and its loss may thus
dispose tumor cells toward uncontrolled proliferation
[17, 18]. Furthermore, TET enzymes, which oxidize 5mC
to produce 5hmC, often exhibit mutations or transcrip-
tional downregulation in many different types of cancers,
especially in hematological malignancies and gliomas
[18–21]. The dioxygenase activity of TET proteins is
dependent on the presence of α-ketoglutarate, which
acts as a catalytic cosubstrate for 5hmC production [22].
Intriguingly, isocitrate dehydrogenase enzymes 1 (IDH1)
and 2 (IDH2), which are normally able to produce α-
ketoglutarate through the decarboxylation of isocitrate,
are mutated in many human cancers. IDH mutations not
only inhibit their ability to produce α-ketoglutarate but
result in the production of the oncometabolite 2-
hydroxyglutarate (2HG), which is able to directly inhibit
the activity of TET proteins [20, 22, 23].
Thus, 5hmC patterning across the tumor genome may
act as a hallmark of cancer development and progres-
sion. However, the locus- and gene-specific roles of
5hmC and their significance in tumorigenesis have not
yet been well characterized in non-neuronal solid tu-
mors, including prostate cancer (PCa).
PCa is the most common malignancy and the second
highest cause of death from cancer in men worldwide
[24]. Currently, the gold standard for PCa diagnosis is
prostate-specific antigen (PSA) testing. However, due to
its high false positive detection rate and the inability of
PSA levels to differentiate between indolent and aggres-
sive disease, the widespread usage of PSA screening has
resulted in frequent overdiagnosis and overtreatment of
the disease, an issue made critical by the significant mor-
bidity associated with radical treatment [25–27]. This
issue is further complicated by extensive tumor multifo-
cality and heterogeneity. A majority of PCa patients
present with multiple nonclonal foci of disease, several
of which may possess differential histologic grades.
Thus, genetic heterogeneity in PCa is not only wide-
spread between patients but also within single prostate
tumor specimens. Individual patients may thus possess
multiple distinct genomic profiles at each tumor focus,
complicating PCa diagnosis, prognostication, and devel-
opment of treatment strategies [28–30].
Epigenetic alterations also contribute to PCa tumor
heterogeneity, with locus-specific variability in cytosine
base methylation (5mC) occurring concurrently with
copy-number alterations in primary prostate tumors
[31]. Although global hypomethylation changes are a late
event in PCa, associated with metastatic progression
[32], promoter hypermethylation is an early and frequent
event in prostate carcinogenesis. Hypermethylation-
induced silencing of the tumor suppressor glutathione
S-transferase P1 gene (GSTP1) is the most frequent
DNA aberration in PCa, while promoter hypermethyla-
tion of GSTP1, RASSF1A (Ras association domain family
1 isoform A), and APC (adenomatous polyposis coli)
correlates with PCa stage [33, 34].
Thus, comprehensive characterization of the 5hmC
modifications underlying PCa development and, conse-
quently, the mechanisms of epigenetic regulation in PCa
may help to address these issues. Investigation of differ-
ential patterns of 5hmC and 5mC distribution across
genomic features (intergenic, intronic, exonic, promoter,
DNAse I hypersensitive site, or CGI regions) could
provide important insights into prostate cancer
pathogenesis.
In this study, we aim to determine the biological role
of aberrant 5hmC patterning in regulating biological
pathways and key candidate genes in prostate
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tumorigenesis. We have used a whole-genome next-
generation sequencing strategy to investigate the dy-
namic interplay between locus-specific 5mC and 5hmC
marks and their relationship with altered gene expres-
sion, performing one of the first integrative analyses of
its kind in prostate cancer. Our data shows that 5hmC
marks display differential effects on gene regulation
based on locus-specific changes unique to cancer cells
and that it may play a critical role in governing central
tumorigenic pathways related to signaling and cellular
proliferation in prostate cancer.
Results
Genome-wide locus-specific hypermethylation and global
reduction of hydroxymethylation occurs in prostate
cancer cells compared to normal prostate
In order to investigate the distribution of 5mC and 5hmC in
the prostate cancer genome, we performed next-generation
sequencing (NGS) following methyl-binding protein capture
(MBD-seq, n = 3) and hydroxymethyl-selective chemical
labeling (hMeSeal-seq, n = 1) in a representative normal
prostate tissue-derived cell line (RWPE-1) and a xenograft-
derived prostate carcinoma cell line (22Rv1). Profiling
of these epigenetic marks across RefSeq-annotated genes
revealed dramatic differential hypermethylation across all
genomic features in 22Rv1 as compared to RWPE-1, with
gene expression lowering in concordance with increased
methylation peak density. In contrast, marked global loss
of absolute 5hmC was noted across the 22Rv1 genome
(Additional file 1: Figure S1), while locus-specific alterations
of both marks could be observed across genes (Fig. 1).
5mC and 5hmC show differential locus-specific abun-
dance in prostate cancer
As locus-specific 5hmC is poorly characterized in pros-
tate cancer, and due to the lowered distribution of 5hmC
in cell culture [35], we first set out to determine the val-
idity of our cell line hydroxymethylation profiling.
hMeSeal-seq samples chosen for analysis displayed sig-
nificant normalized read enrichment compared to input
samples (Additional file 1: Figure S2), while dot blot ana-
lysis of genomic DNA from both cell lines showed corre-
sponding evidence of 5hmC (Additional file 1: Figure
S3). Furthermore, the proportion of promoter, inter-
genic, and CGI hydroxymethylation in both cell lines is
significantly lower than one would expect from random
genomic distribution of the 5hmC mark across CpGs,
indicating the presence of locus-specific patterning in
our samples (Additional file 1: Table S1). Validation of
hMeSeal kit specificity was also performed via the test-
ing of control oligomers (Additional file 1: Figure S4). Fi-
nally, in order to validate our 5hmC marks in RWPE-1,
we performed hydroxymethylated DNA immunoprecipi-
tation sequencing (hMeDIP-seq) on a separate biological
replicate (n = 1) from the same normal cell line. Specificity
of the hMeDIP antibody was verified via internal spike-in
of control sequences (Additional file 1: Table S2). We
found that 55.8 % of hydroxymethylated gene regions
(6324 unique genes) detected by our hMeSeal technique
were also detected in hMeDIP-seq, of which 4.1 % (repre-
senting 257 genes) bore 5hmC peaks with at least partial
overlap in exactly the same 0.48–1.5-kbp regions (Fig. 2a).
hMeDIP-seq samples were sonicated separately from
Fig. 1 Locus-specific differential distribution of methylation and hydroxymethylation in normal prostate versus prostate cancer cell lines. Linear
representation of hMeSeal-seq (top) and MBD-seq (bottom) peaks in representative normal prostate (RWPE-1) or prostate cancer (22Rv1) cells
across the representative gene RasGEF domain family, member 1a (RASGEF1A). Top: generalized and locus-specific hypohydroxymethylation in
22Rv1. Blue boxes indicate representative regions exhibiting strong hydroxymethylation peaks in RWPE-1 and weak or absent hydroxymethylation
peaks in 22Rv1. Asterisk indicates hydroxymethylated region validated by hMeSeal-qPCR testing. Bottom: locus-specific differential methylation
between cell lines. Red boxes indicate representative regions showing strong methylation peaks in 22Rv1 and weaker peaks in RWPE-1. Note that
certain regions also exhibit locus-specific methylation in RWPE-1 and not in 22Rv1
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hMeSeal-Seq samples, resulting in a different pattern of
random shearing and making it highly unlikely that the
observed overlap was generated by random chance. Peak
distribution in both techniques did not significantly differ
in all genomic features with the exception of DNAse
I hypersensitive sites (DHSs), further confirming our
hMeSeal-seq results (Additional file 1: Figure S5).
Next, we compared the abundance of differential methy-
lation and hydroxymethylation peaks proximal to RefSeq
genes between both cell lines (Fig. 2b), validating the spe-
cificity of MBD capture through quantitative PCR (qPCR)
(Additional file 1: Figure S6). 22Rv1 had more than twice
the number of differentially methylated annotated peaks
or differentially methylated regions (DMRs) compared to
RWPE-1. However, the locus-specific distribution of
methylation marks differed between cell lines, with signifi-
cant increases in the proportion of 5mC marks in CGIs
and DHSs in cancer (Additional file 1: Figure S7A). DHSs
Fig. 2 Correlation between locus-specific methylation or hydroxymethylation and gene expression. a Validation of hMeSeal-Seq results by hMeDIP-
Seq. Left: 62.6 % of genes detected as hydroxymethylated in RWPE-1 by hMeSeal were also detected as hydroxymethylated using hMeDIP, while 2.3 %
of peaks from these genes were called in exactly the same chromosomal location using both methods. Right: genomic feature distribution for peaks
called in the same regions in both hMeDIP- and hMeSeal-seq. Some features may overlap each other, and thus one peak may be accounted for more
than once. b Total peaks called from sequencing data in normal and prostate cancer cell lines. Peaks called across three replicates for MBD-Seq or
within one single replicate for hMeSeal-seq. c–f Differentially methylated (c, d) and differentially hydroxymethylated (e, f) regions for both cell lines
stratified by genomic feature. Bar graphs depict the relative abundance of each mark within each of three expression tiers from microarray analysis.
Asterisks represent significant p values (p < 0.05, chi-square test for trend) indicating correlation between the presence of 5mC or 5hmC marks in a
given region and gene expression within each cell line. Upward trend of bars, when significant, indicates a positive correlation of a locus-specific mark
with gene expression. Significant downward trend indicates negative correlation
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are indicative of open chromatin and gene regulatory ele-
ments [36], and we obtained this dataset for RWPE-1
only. We observed significantly less proportional pro-
moter methylation in 22Rv1 as compared to RWPE-1.
These findings contrast with typical patterns of promoter
hypermethylation in cancer and may potentially indicate
site-specific derepression of certain genes. In contrast, the
proportion of promoter CGI methylation was significantly
greater in 22Rv1 than in RWPE-1, in accordance with the
conventional methylation paradigm in cancer.
22Rv1 differential hydroxymethylation was signifi-
cantly reduced in both overall peak number and propor-
tionality of enrichment in exonic, promoter, CGI, and
RWPE-1 DHS genomic features. However, proportional
levels of intronic hydroxymethylation did not signifi-
cantly differ between cell lines. Intriguingly, proportional
intergenic hydroxymethylation was significantly greater
in cancer compared to normal cells (Additional file 1:
Figure S7B). Furthermore, pathway-based analysis of
intergenic hydroxymethylation revealed extensive differ-
ential functional enrichment between normal and cancer
cell lines, suggesting a putative role for intergenic 5hmC
in the aberrant upregulation of proliferation androgen
receptor signaling in cancer. While most literature to
date has focused on pathological 5hmC loss, our results
suggest a putative functional role for the presence or
gain of hydroxymethylation marks in cancer.
A novel negative correlation of 5hmC with expression in
gene-proximal intergenic regions
In order to determine the effect of the observed differential
epigenetic mark distribution in 22Rv1 on gene regulation,
we performed integrative analysis correlating (hydroxy)-
methylation-enriched genes stratified by genomic feature to
gene expression levels obtained from publicly available
microarray data for RWPE-1 [Gene Expression Omnibus
(GEO) Accession: GSM375783] (n = 1) and 22Rv1 [GEO
Accession: GSE36135] (n = 3). We divided the expres-
sion data into three equal tiers representing low, me-
dian, and high relative expression and correlated
genes significantly differentially enriched for either
5mC or 5hmC marks to expression within each tier
(Additional file 1: Table S3 and S4).
We found gene expression to exhibit negative correl-
ation with methylation enrichment in CGIs (both within
and outside core promoter regions) and positive correl-
ation with methylation in genic regions and regions
within 5 kbp of UCSC RWPE-1 DHSs in both cell lines,
as expected (Fig. 2c, d). Correlations between 5mC and
expression tended to be more robust in the cancer cell
line, with strong negative correlation to expression also
observed for intergenic and promoter methylation alone
in 22Rv1.
Significantly, we observed several novel correlations
between hydroxymethylation and gene expression in the
prostate. Hydroxymethylation enrichment in promoters,
CGIs, and CGIs within the core promoter region corre-
lated positively with gene expression in normal prostate,
while a similar correlation with expression in these fea-
tures was not observed in cancer (Fig. 2e–f ). These find-
ings contrast with the proportional gain of promoter
and CGI 5hmC observed in pancreatic cancer [37]. Intri-
guingly, however, we observed a novel negative correl-
ation between hydroxymethylation enrichment in
intergenic regions and expression of the genes with tran-
scription start sites (TSS) closest to the 5hmC mark.
This correlation was strengthened in cancer, in contrast
to the weakening of all other 5hmC expression trends.
Furthermore, while 5hmC in genic regions and within
5 kbp of UCSC RWPE-1 DHSs exhibited linear positive
correlation with gene expression in normal prostate
(similar to 5mC), this correlation was strongly altered in
prostate cancer, where the presence of hydroxymethyla-
tion in these features showed nonlinear correlation with
expression in the median tier. This trend persisted des-
pite the significant decrease of 5hmC in cancer observed
in exonic and DHS-proximal regions and may indicate
altered functionality of 5hmC marks in prostate cancer.
The same correlation was also performed for RWPE-1
hMeDIP-seq data (Additional file 1: Table S5), where
intergenic, genic, and DHS-proximal trends from
hMeSeal-seq were strongly corroborated (Additional
file 1: Figure S8).
Absence, gain, and retention of 5hmC differs significantly
by genomic region between normal and cancer cell lines
We examined absolute peak regions where 5hmC marks
detected in RWPE-1 either overlapped with peak regions
detected as having 5mC marks in 22Rv1 (5hmC “ab-
sence”) or 5hmC marks in 22Rv1 (5hmC “retention”), as
well as peaks where 5mC marks in RWPE-1 overlapped
with 5hmC marks in 22Rv1 (5hmC “gain”). We then
tested these peak regions, stratified by genomic location,
to determine genomic features where the frequency of
occurrence of these overlapping peaks could not be ex-
plained by either random change in RWPE-1 epigenetic
marks or by random distribution of 22Rv1 marks within
each genomic feature (Additional file 1: Table S6).
Peaks located within exonic, promoter, or RWPE-1 DHS
genomic features exhibited greater 5hmC depletion than
expected from the proportion of global RWPE-1 5hmC or
22Rv1 5mC; however, they did not significantly differ from
expected values for random 5hmC retention or gain in
cancer (Table 1). In other words, peaks within these fea-
tures were far more likely to exhibit absence of 5hmC in
cancer than to gain or retain it (Additional file 1: Table
S7), suggesting that loss of 5hmC within these specific
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features may be especially important in tumorigenesis. In
contrast, intergenic regions in cancer showed far less gain
of 5hmC than expected, despite being the only region in
which proportional 5hmC absence in 22Rv1 was non-
significant. Intriguingly, both absence and gain of 5hmC
was greater than expected within CGIs, while intronic re-
gions showed significantly less gain of 5hmC than ex-
pected. Unlike all other features tested, however, the
proportions of peak regions showing 5hmC absence, gain,
or retention in intronic regions did not significantly differ
from each other. These findings further indicate that
changes in 5hmC regulation and functionality in cancer
differ between specific genomic features. However, despite
the significant changes in 5hmC absence in both intronic
and exonic regions, genic changes (comprised of the sum
of intronic, exonic, and UTR regions) in 5hmC status
were not found to be significantly different from random
distribution in any category.
Biological pathways regulated by 5mC and 5hmC marks
differ significantly between normal prostate and prostate
cancer
We performed pathway analysis on genes enriched in ei-
ther 5mC or 5hmC differential marks within each tier of
expression and genomic feature. To identify differential
gene regulation by each mark in normal versus cancer,
we compared the most significant and specific annota-
tion terms (defined by grouping similar enriched path-
ways using the MCODE clustering algorithm and
manually labeling the groups), identified via the Gen-
omic Regions Enrichment of Annotation Tool (GREAT),
between cell lines (hypergeometric test over regions;
false discovery rate (FDR) < 0.05). Individual enrichment
maps were generated for each feature and expression tier
within each cell line prior to pathway comparison
(Fig. 3a).
Pathway enrichment for differentially methylated genes
was primarily observed within CGIs for 22Rv1, where
multiple genes exhibiting CGI methylation and function-
ally enriched for annotations related to the regulation of
cell proliferation, adenylate cyclase activity, and lyase ac-
tivity displayed lowered expression in cancer compared
to normal (Additional file 1: Figure S9A). In contrast,
annotations for differentially methylated genes in exonic
regions were primarily enriched for core cellular func-
tions in both cell lines (Additional file 1: Figure S9B–
S9C). Similarly, although differential intronic methyla-
tion patterns showed enrichment for core pathways in
both cell lines (Additional file 1: Figure S10A–S10B),
most genes did not exhibit concordant differential ex-
pression tiers from the normal to the cancer cell line.
Contrary to our expectations, 5hmC expression path-
way trends paralleled 5mC expression trends within CGI
and exonic regions in cancer. While hydroxymethylated
genes in CGIs remained unenriched for relevant path-
ways in RWPE-1 cells (Additional file 1: Figure S11A),
annotations related to Akt, Wnt, and mTor signaling, as
well as inhibitory p53 feedback loops, were abundant
within highly expressed genes exhibiting CGI hydroxy-
methylation in 22Rv1 (Additional file 1: Figure S11B).
However, all genes involved were also highly expressed
in normal cells.
Exonic hydroxymethylation terms, in contrast, were
not significantly enriched in 22Rv1 (data not shown) but
displayed enrichment within the highest tier of expres-
sion for a diverse range of pathways (including house-
keeping genes expressed across 19 normal tissues, genes
able to induce cell death, and vitamin D metabolism)
within RWPE-1 (Fig. 3b). Furthermore, many of these
genes showed reduced expression in our cancer cell line,
which may indicate a role for exonic 5hmC in the nor-
mal regulation of core cellular functions.
Similar to intronic 5mC-expression profiling patterns,
hydroxymethylated intronic regions in RWPE-1 showed
few significant pathway annotations within the lowest
tier of expression (Fig. 3c), unlike 22Rv1 (Fig. 3d).
Table 1 Locus-specific hydroxymethylation changes in cancer. 5hmC changes were described by the overlap of 5mC and/or 5hmC
marks between cell lines. Overlapping 5mC or 5hmC marks were compared to the overall distribution of each mark within each cell











Intergenic Genic Exonic Intronic Promoter CpG Island RWPE-1 DNaseI
hypersensitive sites
5hmC “Absent” RWPE-1 5hmC 0.051 0.666 <0.0001*,** 0.005*,*** <0.0001*,** <0.0001*,** <0.0001*,**
22Rv1 5mC <0.0001* 0.311 0.002*,** 0.001*,*** <0.0001*,** <0.0001*,** <0.0001*,**
5hmC “Retained” RWPE-1 5hmC 0.302 0.01 0.039 0.169 0.487 0.593 0.067
22Rv1 5hmC 0.013 0.547 0.452 0.834 0.115 0.001* 0.944
5hmC “Gained” RWPE-1 5mC 0.003*,*** 0.975 0.175 0.834 0.5 <0.0001*,** 0.007*
22Rv1 5hmC <0.0001*,*** 0.026 0.025 0.538 0.71 <0.0001*,** 0.511
*Significant p values as determined by the chi-square test with Bonferroni correction for multiple testing applied; **5hmC is significantly more likely to be absent,
gained, or retained within the given region than expected; ***5hmC is significantly less likely to be absent, gained, or retained within the given region
than expected
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However, extensive enrichment was observed within the
highest expression tier for pathways related to DNA
damage repair, integrity checkpoints, apoptosis, and
direct p53 effectors (Fig. 3c). Interestingly, annotations
related to prostate cancer, the c-Myc pathway, and telo-
mere extension were also observed within the normal
cell line within the highest expression tier. As the
RWPE-1 cell line has been immortalized through the
use of human papillomavirus, these pathways may
be indicative of aberrations incurred from the
immortalization process. In cancer, significant pathway
enrichment was seen in both low and high expression
tiers, with polycomb repressive complex 2 (PRC2) tar-
gets and genes known to be downregulated in PCa
enriched in the lowest expression tier while pathways re-






Fig. 3 Pathway regulation by methylation and hydroxymethylation marks in normal prostate and prostate cancer. a Representative example of an
enrichment map generated using Cytoscape depicting annotations significantly enriched for genes exhibiting intronic hydroxymethylation and
highest tier expression levels in 22Rv1 alone as compared to all genes detected in both cell lines via hMeSeal-Seq. Annotated using the GREAT
hypergeometric test over regions (p value < 0.05, FDR < 0.1, Jaccard’s similarity coefficient < 0.25). Left: select clusters of related pathways (nodes)
in the enrichment map are highlighted (clusters identified using MCODE). Right: zoom in to signaling pathway enrichment map cluster. Below:
pathway enrichment annotations from GREAT for hydroxymethylation within RWPE-1 cells, overlapping (b) exonic or (c) intronic regions and
hydroxymethylation within 22Rv1 overlapping (d) intronic or (e) intergenic regions. Pathways further represented by genes within the highest
(high expression) and lowest tier of expression (low expression)
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genes known to be enriched in PCa specifically were ob-
served in the highest expression tier (Fig. 3d). Interest-
ingly, DNA repair and apoptotic pathway enrichment
was also seen within this tier in cancer, although most
genes involved were expressed at the same level in both
normal and PCa cells.
Perhaps most intriguingly, intergenic regions exhibited
pathway enrichment within the lowest tier of expression
unique to 22Rv1 cells. Strikingly, many of these path-
ways were associated with tumorigenic functions
(Fig. 3e), suggesting a putative role for intergenic hydro-
xymethylation in the downregulation of inflammation
and cellular adhesion and the upregulation of epithelial
cell proliferation. Of particular interest, however, was
the presence of 5hmC enrichment in pathways govern-
ing the negative regulation of androgen signaling. Fur-
thermore, differentially hydroxymethylated genes within
this pathway, including the PCa-inhibitory genes se-
creted fizzled-related protein 1 (SFRP1) and Dab,
mitogen-responsive phosphoprotein homolog 2 (DAB2),
exhibited significantly lower expression in cancer than in
the normal cell line. In sharp contrast, RWPE-1 showed
few significant functional annotations for low-tier inter-
genic hydroxymethylation marks (Additional file 1:
Figure S12). Overall, exonic and intergenic regions
showed the most striking differential pathway enrich-
ment between normal and cancer cells for both 5mC
and 5hmC marks. Differentially hydroxymethylated
genes from high-level exonic pathways in RWPE-1 and
low-tier intergenic pathways in 22Rv1 exhibited large
differences in expression between cell lines, potentially
indicating a critical role for aberrations in exonic and
intergenic patterning of 5mC and 5hmC marks in
cancer.
Locus-specific 5mC and 5hmC marks share a novel
cooperative role in the regulation of functional pathways
We compared biological pathway annotations for genes
enriched in both 5mC and 5hmC within each cell line
by expression tier and genomic feature in order to deter-
mine whether or not intercellular differences observed
in the type of epigenetic modifications resulted in
significant differences in pathway regulation (Additional
file 1). Surprisingly, we found that a significantly higher
proportion of pathways enriched for both marks in ei-
ther cell line showed intracellular co-enrichment of
5hmC and 5mC within the same expression tier on the
same gene (p < 0.0001). While promoter and CGI methy-
lation and hydroxymethylation marks governed com-
pletely different pathways, genes with intronic 5hmC
marks exhibited strong 5mC and 5hmC co-enrichment
for specific cellular functions in both cell lines (Fig. 4a).
Furthermore, while gene-specific methylation and exonic
hydroxymethylation were observed to co-regulate
pathways related to basic cellular functionalities such as
ATP binding and hydrolase activity in RWPE-1 (Fig. 4b),
this co-regulation was entirely lost in 22Rv1, mirroring
the loss of exonic 5hmC marks in cancer. Intriguingly,
co-occurrence of 5mC with intergenic 5hmC epigenetic
marks was observed in 22Rv1, but not in RWPE-1, coin-
ciding with high-level functional annotations in the low-
est tier of expression including signaling, regulation of
cellular proliferation and cAMP biosynthesis regulation
in cancer (Fig. 4c).
Additionally, we found that most hydroxymethylated
intronic pathways showing concomitant 5mC enrich-
ment in cancer were related to basic cellular functions,
such as binding, protein localization, and cytoskeletal
organization, within each expression tier (Fig. 4d). This
observation contrasts sharply with hydroxymethylated
intronic co-enrichment pathways in RWPE-1, where
basic processes predominated in the middle and lowest
expression tiers (Fig. 4e). However, annotations for genes
exhibiting both marks within the highest tier of expres-
sion were enriched for multiple highly specific processes,
including pathways related to the electron transport
chain as well as binding of both NF-κB and p53. This
data provides novel evidence for the highly locus- and
gene-specific dysregulation of 5hmC in governing
oncogenesis.
Genes involved in key differential biological processes are
detectable via hMeSeal-qPCR
We chose representative genes for validation which were
localized to hydroxymethylated regions detected by both
hMeSeal-seq and hMeDIP-seq in RWPE-1, were not
hydroxymethylated in 22Rv1, and overlapped RWPE-1
DHSs (Additional file 1: Table S8). Selected genes were
not methylated in either cell line (Additional file 1:
Figure S13). Cullin 2 (CUL2) bore methylation marks
overlapping hydroxymethylation peaks in RWPE-1, but
not in 22Rv1; in contrast, RasGEF domain family mem-
ber 1a (RASGEF1a) and histidine triad nucleotide-
binding protein 1 (HINT1) were methylated in the same
region in 22Rv1 (exhibiting 5hmC “loss” in cancer while
not being methylated in RWPE-1). RASGEF1a and
CUL2 were located in intronic regions, while HINT1 re-
fers to an intergenic 5hmC peak located most closely to
the TSS of HINT1. Lastly, all genes chosen possessed ro-
bust and clear 5hmC enrichment peaks within the over-
lapping regions, with corresponding absent or low peaks
in input samples (Fig. 5a).
In order to validate the specificity of our sequencing
data and quantify the relative 5hmC levels, we per-
formed qPCR with standard curve protocol following
hMeSeal enrichment of genomic RWPE-1 and 22Rv1
DNA. We used primers flanking the identified enrich-
ment peaks for CUL2, RASGEF1a, and HINT1, as well
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as the negative control gene homeobox D8 (HOXD8).
HOXD8 was found to be strongly methylated in RWPE-
1 (Additional file 1: Figure S14) and was not hydroxy-
methylated in either cell line. Negative control capture
reactions lacking UDP-azide-glucose followed by qPCR
were performed simultaneously across three technical
replicates. Enrichment of HOXD8 was not detected via
qPCR, confirming the specificity of our capture reaction.
CUL2, RASGEF1a, and HINT1 positive and negative
control qPCR reactions were normalized to HOXD8
negative control using the ΔΔCt method, obtaining fold
enrichment values of 2.73×, 3.20×, and 4.39×, respect-
ively (Fig. 5b), while enrichment was not detectable in






Fig. 4 Locus-specific co-enrichment of methylation and hydroxymethylation marks in normal prostate versus prostate cancer. a Genomic distribution
of 5hmC marks exhibiting co-incidence with 5mC in normal prostate versus prostate cancer cells. Co-incident marks were defined as precise regions
within the same cell line containing both 5mC and 5hmC marks which exhibited at least partial overlap. b–e Pathway enrichment annotations from
GREAT for co-incident marks in (b) RWPE-1 exonic regions, (c) 22Rv1 intergenic regions, or intronic regions in (d) 22Rv1 or (e) RWPE-1 cells. Log
p values for methylation marks (top) and hydroxymethylation marks (bottom) are shown
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results and show that locus-specific detection of 5hmC
enrichment is possible in the prostate and prostate can-
cer cell lines.
Discussion
Recent studies have provided direct evidence supporting
a key role for 5hmC in regulating transcription, both
through the structural influence of locus-specific 5hmC
hemimodification on transcription factor binding [38]
and the active recruitment of 5hmC “readers” regulating
transcription as described in murine retinal development
[39]. In hematological cancers such as acute myeloid
leukemia, locus-specific loss of 5hmC has been nega-
tively correlated with gene expression in intronic, genic,
promoter, and distal regulatory regions [40]. However,
previous studies in solid tumors have focused primarily
on mapping genome-wide loss of hydroxymethylation
independently of genomic features [7, 9, 21]. Exceptions
include pancreatic cancer, in which a positive association
was found between promoter or gene body 5hmC en-
richment and gene expression in both normal and can-
cer cells [30], and in colon cancer, in which promoter
hydroxymethylation in normal cell lines was found to
render them resistant to oncogenic methylation gain
[13], and also melanoma, in which enrichment of onco-
genic functions was found in genes losing 5hmC marks
and gaining 5mC marks in cancer [41].
In prostate cancer, 5hmC has been found to be both
globally depleted and inversely correlated with cell pro-
liferation [7, 37] and has recently been implicated as an
inhibitory mark downregulating gene expression in
metastatic PCa cell line models [42], in direct contrast
to our findings. As the distribution of hydroxymethyla-
tion marks differs significantly between tissue types [9],
this discrepancy may be reflective of differences between
PCa models or may even be indicative of differential
genomic feature-specific effects of 5hmC modification.
To date, the locus-specific role of 5hmC modification in
governing gene expression and functionality has not
been identified in PCa. Furthermore, while oncogenic
pathway enrichment has been found in regions exhibit-
ing 5hmC gain in pancreatic cancer [37], our data did
not reveal significant pathway enrichment for similar
genes in our cell lines. This may be due to significant
a
b c
Fig. 5 Validation of differentially hydroxymethylated regions (DHMRs) via hMeSeal-qPCR. a Top: IGV Genome Browser representation of absolute
hydroxymethylation peaks called in single replicate from hMeSeal-seq data within regions showing hydroxymethylation in both hMeSeal- and
hMeDIP-seq and compared to unenriched input control for three representative genes for validation: CUL2, RASGEF1a, and HINT1, and HOXD8
negative control. Peak strength indicated by height of representative peak within replicate or input control (scale shown in square brackets).
Colored vertical bars within peaks represent differences between sequenced bases and the hg19 reference genome. Bottom: Blue horizontal bars
indicate the presence of introns. Green horizontal bars indicate CGIs. Red boxes indicate the position of the hMeSeal-qPCR amplified segment
depicted relative to the overall location of the gene (figure not to scale). Gene diagram adapted from UCSC Genome Browser. b Validation of
hydroxymethylation gene enrichment for RWPE-1. Enrichment of hydroxymethylation detected via hMeSeal-qPCR for candidate genes, CUL2,
RASGEF1a, and HINT1, within RWPE-1 compared to HOXD8 negative control and normalized relative to 0.03 % input control using the ΔΔCt
method (mean values ± standard deviation, n = 3). All genes were compared to negative hMeSeal control reaction performed without UDP-azide-
glucose and representing nonspecific binding. c Hydroxymethylated gene enrichment for RWPE-1 versus 22Rv1. Differential detection of genes
identified as uniquely hydroxymethylated in RWPE-1, but not 22Rv1, by hMeSeal-seq via hMeSeal-qPCR compared to negative control hMeSeal
reaction and normalized relative to 0.03 % input control using the ΔΔCt method (mean values ± standard deviation, n = 3)
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global loss of 5hmC marks in cell culture further impair-
ing detection of hydroxymethylated regions in our PCa
cell line [35] or an example of a tissue-specific 5hmC
profile.
One important caveat of our cell line model is the
rapid global loss of 5hmC observed by Nestor et al. in
cell lines almost immediately upon culture and passaging
[35]. High-passage mouse embryonic fibroblast cell lines
and primary T cell cultures were found to lose 5hmC to
such a degree that clear hydroxymethylation patterning
was lost from the tissues or primary cells of origin. Loss
of 5mC in culture, however, was much milder and
allowed for the retention of patterning. Although global
levels of 5hmC in our cell lines were low, it should be
noted that our validation of hMeSeal-seq data via both
genome-wide hMeDIP-seq and locus-specific hMeSeal-
qPCR contraindicates the loss of clear 5hmC patterning
within our cell line models.
The overall distribution of 5mC and 5hmC marks
within each cell line showed an absolute methylation
peak increase and hydroxymethylation peak decrease for
all genomic features in cancer. However, the lack of sig-
nificant intronic 5hmC difference between cell lines,
coupled with our observation that intronic regions are
the most likely to gain 5hmC in PCa, may indicate that
intronic hydroxymethylation is both tightly regulated
and potentially critical for basic cellular function. Simi-
larly, the proportional gain of intergenic 5hmC and its
status as the most likely feature to retain 5hmC in
cancer may indicate either a lack of importance for
intergenic 5hmC marks or, conversely, a key regulatory
function in oncogenic transformation. However, the
strong negative correlation between intergenic hydroxy-
methylation and gene expression in both cell lines, in
addition to the significant pathway enrichment in genes
bearing intergenic 5hmC and in the lowest tier of ex-
pression for terms related to androgen receptor regula-
tion, inflammation, and cellular adhesion, provides
strong support for the latter hypothesis. Our findings
may indicate novel biological roles for intergenic 5hmC
modifications located outside of regulatory regions and
intron-specific 5hmC marks gained in cancer. Since
many different factors can contribute to results from
pathway-based analysis, further functional validation of
implicated candidate genes will be performed using in
vitro cell lines and animal models in order to verify these
findings.
In contrast, although CGIs were found to be generally
depleted for 5hmC marks in both of our cell lines, to
such an extent that expression patterning was entirely
lost in cancer, the extent of 5hmC depletion and gain
within these features suggests that specific changes in
CGI hydroxymethylation may be especially important
for not only downregulation of genes in PCa but their
upregulation as well. Interestingly, despite the significant
exonic absence and intronic retention of 5hmC in can-
cer, genic regions exhibit no significant differences in
5hmC from random changes in either cell line, suggest-
ing that the level of 5hmC retention in introns matches
the magnitude of 5hmC depletion in exonic regions.
Therefore, although many studies examine genic 5hmC
alterations at a global level in development and disease,
the observed distinct function of 5hmC within exons
and introns in our samples underscores the need for fur-
ther functional studies of 5hmC to be performed in a
genomic feature-specific manner.
We found that functional mark distribution clearly sug-
gested a distinct biological role for 5mC and 5hmC within
our cell lines. Our analysis revealed several major biological
pathways exhibiting differential epigenetic regulation in
normal and cancer cell lines. Within 22Rv1 CGIs, 5hmC
was positively correlated with genes involved in signaling
processes promoting cell proliferation and migration and
downregulating apoptotic p53 signaling, while 5mC was
simultaneously negatively correlated with expression of
genes regulating cyclic AMP (cAMP) generation. These ob-
servations reflect the contrasting relationships between
CGI methylation or hydroxymethylation and expression.
Additionally, we observed distinct biological roles for
5mC and 5hmC marks between cell lines. Intronic
hydroxymethylation was not significantly lost in our can-
cer cell line compared to normal, indicating that 5hmC
may undergo specific redistribution in tumorigenesis.
For example, while RWPE-1 intronic hydroxymethyla-
tion appears to positively regulate genes related to cal-
pain I (uCalpain) activity in cell adhesion, 22Rv1
intronic 5hmC is enriched for pathways related to cal-
pain II (mCalpain) involvement in cell motility. Intri-
guingly, almost all RWPE-1 hydroxymethylated genes
involved in the tumor necrosis factor pathway exhibit
lowered expression in 22Rv1, indicating a critical role
for intronic 5hmC in governing this pathway. Due to the
potentially confounding effects of immortalization in our
cell lines, future functional analysis will be performed in
tissue samples and in vivo models in order to further in-
vestigate the differential functionality implied by path-
way analysis.
Many of the annotations observed for genes co-
incident for 5hmC and 5mC marks in either cell line are
related to basic cellular functions, which are often broad
categories involving many genes [41, 43]. However, we
also observed striking differences in both mark distribu-
tion and annotations between cell lines and genomic fea-
tures with specialized pathways that are more likely to
be indicative of true functional differences in epigenetic
regulation.
Co-incidence of 5mC with exonic 5hmC was lost in
22Rv1 compared to normal, along with overall exonic
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5hmC levels, representing a loss of co-incident marks in
basic cellular pathways observed in RWPE-1. Intri-
guingly, this observation stands almost in direct contrast
to intronic 5hmC and 5mC mark profiling in cancer, where
intronic retention of both marks was seen for terms related
to basic cellular functionality. This may possibly indicate
their more essential role in basic cell survival than exonic
modifications. Alternatively, it may also suggest that the
genes involved in the cellular processes enriched for 5mC
co-incidence with exonic 5hmC are more likely to exert
functions inhibitory to tumor growth than those in intronic
regions. Considering that overall 5hmC levels within in-
trons are still lost in 22Rv1, an examination of noncoding
RNA expression from intronic regions exhibiting differen-
tial epigenetic regulation in cancer might reveal the func-
tion of specific mark retention or gain in PCa.
The proportional increase of intergenic 5hmC in can-
cer, coupled with its robust correlation to low gene ex-
pression, may indicate a novel cooperative role for
locus-specific 5hmC and 5mC in the regulation of
tumor-suppressive functions in both normal and aber-
rantly modified PCa cell lines. Furthermore, this data
suggests not only the precise dysregulation of nonessen-
tial 5hmC in intronic pathways related to tumor-
suppressive functions in cancer but also that locus-
specific intergenic gain of 5hmC may be used by tumor
cells in conjunction with aberrant methylation elsewhere
on the gene to actively suppress antitumor function.
In accordance with our novel findings regarding the
role of intronic and intergenic hydroxymethylation in
PCa, we chose two intronic genes—RASGEF1a and
CUL2—and one intergenic gene—HINT1—for validation
studies based primarily on the robustness of concord-
ance between hMeDIP and hMeSEAL peaks, as well as
lack of methylation and functionality in cancer.
Overexpression of RASGEF1a, an activator of the RAS
family of oncogenes promoting cellular migration, is
linked to oncogenesis in cholangiocarcinoma [44, 45].
The hydroxymethylation peak detected for RASGEF1a
was located at the exon-intron boundary, a region
known to exhibit neuronal 5hmC enrichment in the lit-
erature [11]. In normal cells, HINT1 exerts tumor-
suppressive effects through inhibition of the Wnt path-
way and the promotion of both apoptosis and p53 ex-
pression and is known to undergo transcriptional
silencing via promoter hypermethylation in colon and
non-small cell lung cancer [46, 47]. Despite exhibiting
the weakest peak of all three genes chosen for validation,
the HINT1-proximal 5hmC peak was still robustly de-
tected by hMeSeal-qPCR, confirming that intergenic
5hmC marks can also be reliably detected using our
whole-genome sequencing strategy. Finally, CUL2 was
chosen as a representative validation gene due to the
strength of its intronic hMeSeal-seq peak and its
function as a component of the tumor-suppressive Von
Hippel-Lindau complex, inhibiting uncontrolled angio-
genesis via ubiquitination and degradation of hypoxia-
inducible factor 1 alpha (HIF1α) [48]. As all three genes
were able to be detected specifically in the normal cell
line, we have verified the ability of our hMeSeal-Seq
technique to reliably and specifically detect differentially
distributed and weakly hydroxymethylated genes.
Since our strategy for selecting representative candidates
was successful, we propose that further 5hmC candidates
be selected in this manner. Key candidate genes involved
in the regulation of critical oncogenic processes will be
identified from region-specific central biological pathways
exhibiting differential 5hmC modification based on
hMeSeal-seq peak strength, function, annotation signifi-
cance and relevance, putative association with TET en-
zymes, and differential gene expression between normal
and cancer cell lines. Ultimately, these genes will be vali-
dated in primary tissue samples from both normal and
early-stage cancer, as we expect that specific changes in
5hmC marks may be an early event in tumorigenesis.
Conclusions
We demonstrate the highly locus-specific correlation of
hydroxymethylation with gene expression in normal
prostate cells, with a loss of robustness for correlation
with positive expression in intergenic regions as well as
a novel observation of increased robustness in negative
expression correlation. Our findings indicate that loss of
5hmC in exonic, intronic, and CGI genomic regions,
coupled with novel proportional hydroxymethylation
gain in intergenic regions, may constitute important
mechanisms of transcriptional repression in cancer de-
velopment. Simultaneously, integrative pathway analysis
correlating 5hmC to 5mC mark distribution, stratified
by genomic feature, reveals their cooperative role in gov-
erning key biological pathways implicated in 5hmC-
directed regulation of tumorigenesis. The selection of
candidate genes exhibiting differential expression and
epigenetic regulation from these functional pathways
may provide novel avenues for the investigation of new
and pre-existing biomarkers of cancer development.
Our locus-specific integrative analysis of hydroxymethyla-
tion marks is the first study of its kind to be performed in
prostate cancer. Ultimately, our characterization of key cel-
lular pathways exhibiting dynamic enrichment alterations
for 5hmC or 5mC marks may not only allow us to identify
novel biomarkers of disease but may also lead to the discov-
ery of potential therapeutic target genes in PCa.
Methods
Cell culture and DNA extraction
Normal human prostate epithelial cell line, RWPE-1,
was obtained from the American Type Culture
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Collection (ATCC). Human prostate cancer cell line,
22Rv1, was provided by Dr. E. Diamandis (Mount Sinai
Hospital). RWPE-1 cells were cultured with Keratinocyte
serum-free medium (K-SFM) (Invitrogen) supplemented
with 0.05 mg/ml bovine pituitary extract (BPE) and
5 ng/ml human recombinant epidermal growth factor
(EGF). 22Rv1 cells were cultured with RPMI 1640
(Mount Sinai Hospital) with 10 % fetal bovine serum
(FBS). All cells were cultured as a monolayer and main-
tained in a humidified incubator at 37 °C with 5 % CO2.
Genomic DNA was extracted from cells after trypsiniza-
tion, using the QIAamp DNA Mini Kit (Qiagen) follow-
ing the protocol provided.
DNA methylation enrichment and next-generation se-
quencing: MBD-seq
Genomic DNA extracted from RWPE-1 and 22Rv1 cells
was sonicated into approximately 100–300 bp fragments
using a Vibracell Disrupter (SONICS). Sheared genomic
DNA (4 μg) was incubated with methyl-CpG binding
domain 2 (MBD2) protein and magnetic streptavidin
beads provided by the MethylMiner Kit (Invitrogen).
Bound DNA fragments were eluted with the highest
concentration of NaCl buffer (2000 mM). Bound, un-
bound, and input DNA fragments were precipitated
using MinElute PCR Purification Kit (Qiagen) with the
final elution in UltraPure Distilled Water (Invitrogen).
Bound and input DNA was quantified using Qubit 2.0
Fluorometer (Invitrogen). Bound, MBD2-enriched DNA
(20 ng), and input samples (non-enriched) from 22Rv1
and RWPE-1 cells were submitted in triplicate biological
replicates for library preparation (NEBNext® ChIP-Seq
Library Prep Reagent Set for Illumina) and high-
throughput sequencing using the HiSeq 2000 and 2500
(Illumina) at The Centre for Applied Genomics (The
Hospital for Sick Children). Each library generated ap-
proximately 50 million paired-end reads with 5× cover-
age of CpGs.
DNA hydroxymethylation enrichment by glucosylation
and next-generation sequencing: hMeSeal-seq
Genomic DNA extracted from RWPE-1 and 22Rv1 cells
was sonicated into approximately 100–300 bp fragments
using a Q125 sonicator (QSonica). Sheared genomic
DNA (10 μg) was specifically glucosylated at 5hmC by
T4-phage β-glucosyltransferase and incubated with bio-
tin and streptavidin beads provided by the Hydroxy-
methyl Collector Kit (Active Motif ). The final elution of
bound, unbound, and input DNA fragments were
precipitated according to the protocol provided with the
final elution in UltraPure Distilled Water (Invitrogen).
Bound and input DNA was quantified using Qubit
2.0 Fluorometer (Invitrogen). Each replicate of
5hmC-enriched sample was prepared by pooling up
to four hMeSeal reactions. Following, bound/glucosy-
lated 5hmC-enriched DNA (15 ng) and input samples
(non-enriched) from RWPE-1 and 22Rv1 cells were sub-
mitted in triplicates for library preparation (NEBNext®
ChIP-Seq Library Prep Reagent Set for Illumina) and
high-throughput sequencing using the HiSeq 2500 (Illu-
mina) at The Centre for Applied Genomics (The Hospital
for Sick Children). Each library generated approximately
50 million paired-end reads, with 10× coverage of CpGs.
DNA hydroxymethylation enrichment by
immunoprecipitation and next-generation sequencing:
hMeDIP-seq
RWPE-1 genomic DNA from a separate biological repli-
cate was submitted to Arraystar Inc. (Rockville, Mary-
land) where hMeDIP enrichment and NGS processing
were performed. Genomic DNA was sonicated into ap-
proximately 200–600 bp fragments with a Bioruptor
sonicator (Diagenode). Sheared genomic DNA (800 ng)
was end-repaired, A-tailed, and ligated to single-end
adapters following the standard Illumina genomic DNA
protocol. Agarose size-selection was used to remove
unligated adapters. Adaptor-ligated DNA was heat-
denatured at 94 °C for 10 min and rapidly cooled on ice.
Following, the denatured DNA was immunoprecipitated
with 1 μL mouse monoclonal anti-5-hmC antibody
(Diagenode) overnight at 4 °C, with rocking agitation in
400 μL immunoprecipitation (IP) buffer (0.5 % BSA in
PBS). Five immunoprecipitation washes were performed
with ice-cold IP buffer. A nonspecific mouse IgG immu-
noprecipitation was performed as a negative control.
Washed beads were resuspended in TE buffer (with
0.25 % SDS and 0.25 mg/mL proteinase K) for 2 h at
65 °C and then cooled to room temperature. Bound/
immunoprecipitated and unbound DNA fragments were
purified using MinElute columns (Qiagen) and eluted in
16 μL of elution buffer (Qiagen). Immunoprecipitated
fragments (5 μL) were subjected to 14 cycles of PCR
using single-end PCR primers (Illumina). The resulting
reactions were purified with MinElute columns (Qiagen),
after which a final size selection (300–700 bp) was per-
formed by electrophoresis in 2 % agarose. Libraries were
quality controlled by Agilent 2100 Bioanalyzer. An ali-
quot of each library was diluted in elution buffer (Qia-
gen) to 5 ng/μL, and 1 μL was used in real-time PCR
reactions to confirm the enrichment for hydroxymethy-
lated region. The library was denatured with 0.1 M
NaOH to generate single-stranded DNA molecules, and
loaded onto channels of the flow cell (8 pM), and ampli-
fied in situ using TruSeq Rapid SR Cluster Kit (#GD-
402-4001, Illumina). High-throughput sequencing was
performed on the HiSeq 2000 (Illumina) using the Tru-
Seq Rapid SBS Kit (#FC-402-4001, Illumina).
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Bioinformatic analysis of MBD-seq
Sequenced reads were mapped to the reference human
genome (GRCh37, hg19) using Bowtie (v0.12.7) [49]. Sig-
nificantly enriched regions/peaks of methylation were de-
termined using model-based analysis of ChIP-seq (MACS)
algorithm [50], by comparing bound, enriched samples to
input, non-enriched samples. Annotation was performed
using ChIPpeakAnno R package (v.1.12.0) [51] and a cus-
tomized version of Annovar program [52] with RefSeq
genes to determine specific genomic features: promoter
regions (2.5 kb upstream and 500 bp downstream from
the nearest TSS), genic (further defined as 500 bp down-
stream from the nearest TSS), exons, introns, and inter-
genic (defined as greater than 100 kb up/downstream
from the nearest TSS). UCSC CpG island definitions were
used to define CpG islands. RWPE-1 DNase-seq data from
the Encyclopedia of DNA Elements (ENCODE) project
[GEO accession: GSM1008595] was correlated to MACS
peak sets in both RWPE-1 and 22Rv1 cells. The genomic
feature, RWPE-1 UCSC DNAseI peaks, was defined as
within 5 kb of a DNase peak. The following options for
ChiPpeakAnno were used: PeakLocForDistance=“middle,”
FeatureLocForDistance=“middle” for DNase I HS and
CpG data, and FeatureLocForDistance=“TSS” for RefSeq
gene annotations. MACS data was further analyzed using
DiffBind R package (v.1.12.0) [53] to determine three con-
sensus peak sets by requiring that peaks from one, two, or
all three replicates be present at the same location. The
third consensus peak set was subsequently defined as dif-
ferentially methylated regions (DMRs) between RWPE-1
and 22Rv1 cells (fold change >1, FDR < 0.1).
Bioinformatic analysis of hMeSeal-seq
Sequenced reads were mapped to the reference human
genome (GRCh37, hg19) using Bowtie (v0.12.7) [49].
Repitools package [54] was used as an enrichment diag-
nostic screen of sequenced samples, enriched and input.
Significantly enriched regions/peaks of hydroxymethyla-
tion were determined using model-based analysis of
ChIP-seq (MACS) algorithm [50], by comparing bound,
enriched samples to input, non-enriched samples. Anno-
tation was performed using ChIPpeakAnno R package
(v.1.12.0) [51] and a customized version of Annovar pro-
gram [52] with RefSeq genes to determine specific gen-
omic features: promoter, genic, exons, introns, and
intergenic (previously described for MBD-seq). UCSC
CpG island definitions were used to define CpG islands.
RWPE-1 DNase-seq data from the ENCODE project
[GEO accession: GSM1008595] was correlated to MACS
peak sets in both RWPE-1 and 22Rv1 cells. The genomic
feature, RWPE-1 UCSC DNAseI peaks, was defined as
within 5 kb of a DNase peak. MACS data was further
analyzed using DiffBind R package (v.1.12.0) [53] to de-
termine two consensus peak sets by requiring one or
both MACS peaks to be present for a consensus peak to
be called. The first consensus peak set was subsequently
defined as differentially hydroxymethylated regions
(DHMRs) between RWPE-1 and 22Rv1 cells (fold
change >1).
Bioinformatic analysis of hMeDIP-seq
Sequencing image analyses and base calling were per-
formed using Off-Line Basecaller software (OLB V1.8).
After passing Solexa CHASTITY quality filter, se-
quenced reads were mapped to the reference human
genome (GRCh37, hg19) using Bowtie (V2.1.0) [49]. Sig-
nificantly enriched regions/peaks of hydroxymethylation
were determined using model-based analysis of ChIP-
seq (MACS, V2) algorithm [50], by comparing immuno-
precipitated, enriched samples to input, non-enriched
samples (p value < 10−4). Annotation was performed
using the UCSC RefSeq database, where peaks were
mapped to the nearest gene and specific genomic fea-
tures were determined: promoter (2500 kb upstream and
500 bp downstream from the TSS); gene body (500 bp
downstream of the TSS to the TTS), including introns
and exons; and intergenic (remaining regions not de-
fined as “promoter” or “gene body” located more than
100 kb from the nearest TSS). UCSC CpG island defini-
tions were used to define CpG islands. RWPE-1 DNase-
seq data from the ENCODE project [GEO accession:
GSM1008595] was correlated to MACS peak sets in
both RWPE-1 and 22Rv1 cells. The genomic feature,
RWPE-1 UCSC DNAseI peaks, was defined as within
5 kb of a DNase peak.
Statistical analysis: correlation between genome-wide
DNA methylation and hydroxymethylation marks
Specific regions/peaks from genome-wide MBD-Seq and
hMeSeal-seq data where DNA hydroxymethylation over-
lapped methylation, hydroxymethylation overlapped
hydroxymethylation, and methylation overlapped hydro-
xymethylation for RWPE-1 and 22Rv1, respectively, were
identified and stratified by genomic feature as described
previously. Significant proportional difference for modified
regions from the expected proportion of overall RWPE-1
and 22Rv1 marks, such that the frequency of occurrence
of modified regions could be explained by neither random
change in RWPE-1 marks or by random distribution of
22Rv1 marks, was assessed using chi-square test.
Statistical analysis: correlation between genome-wide
DNA methylation or hydroxymethylation and gene
expression
Microarray RNA expression data were downloaded
from GEO DataSets for RWPE-1 [GEO accession:
GSM375783] and 22Rv1 [GEO accession: GSE36135].
Affymetrix probe identifications were linked to gene
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names using the R package (hgu133plus2.db, v.3.0.0),
and a single expression value per gene was selected (a
calculated average between replicates). The resulting
dataset was sorted by expression and divided into three
equal subsets/tiers of genes with low, medium, and high
expression. Consensus peaks from MBD-seq (three sets)
and hMeSeal-seq (two sets) analyses were intersected
with each of the three tiers of genes, from microarray
datasets. Peaks were obtained when found to overlap or
flank genes with low (zero), moderate, or high expres-
sion. Each of the resulting datasets (15 sets) was further
stratified into subsets of peaks differing in their location
according to genomic features (previously defined for
MBD-seq). In addition to the count of peaks for each of
the peak sets defined above, the corresponding count of
associated RefSeq coding genes was also recorded. The
strength of association between peak or gene count and
expression level was assessed using chi-square test, Pear-
son’s correlation coefficient, and Fisher’s exact two-tailed
test, using R package (v.3.1.0). Fisher’s exact test was
performed comparing tier 1 (low expression) to tier 3
(high expression) gene/peak sets.
Pathway analysis of MBD-seq and hMeSeal-seq datasets
correlated with gene expression
Genomic region lists were generated to represent signifi-
cant differentially methylated or hydroxymethylated re-
gions (DMRs or DHMRs), overlapping specific genomic
features, identified by comparing RWPE-1 and 22Rv1
cells. DMR or DHMR lists were further stratified accord-
ing to correlation with microarray RNA expression data-
sets (as described above). Pathway enrichment analysis
was performed on the genomic region lists using the
Genomic Regions Enrichment of Annotations Tool
(GREAT) [55]. The background file submitted contained
a complete list of total methylated or hydroxymethylated
regions in both RWPE-1 and 22Rv1 datasets (no signifi-
cance threshold applied). GREAT results were repre-
sented as an enrichment map (p < 0.05, FDR < 0.1,
Jaccard’s similarity coefficient < 0.25) [56] generated in
the visualization software, Cytoscape (v3.1.0) [57].
Groups of related pathways (nodes) were identified using
the MCODE cluster app and were then manually sum-
marized (circled and labeled in figures) [58]. Addition-
ally, GREAT results were organized into bar graphs
according to the recommended statistic of −log10 (raw
hypergeometric p value) for ranking. Additionally, NGS
(raw peaks) and microarray (raw gene expression) data
were visualized using Circos software [59].
Locus-specific DNA hydroxymethylation detection using
hMeSeal-qPCR
Following hMeSeal technique performed on a separate bio-
logical replicate from hMeSeal-Seq (previously described),
DNA hydroxymethylation levels were analyzed by RT-
qPCR using the 7500 Real-Time PCR Instrument (Applied
Biosystems). Hydroxymethylation levels were calculated
using 2−ΔΔCt method, relative to 2.7 % of input genomic
DNA, and normalized to 0.027 % of input genomic DNA.
A negative control reaction was performed according to
the Hydroxymethyl Collector protocol (Active Motif),
where UDP-azide-glucose was excluded from the glucosy-
lation reaction. In addition, 2.5 μg of sheared genomic
DNA was subjected to each glucosylation reaction, for
both sample and negative control reactions. The PCR as-
says comprised of 5 μl of PerfeCTa® SYBR® Green
FastMix®, Low ROX (Quanta Biosciences), 2 μl of bound
DNA elution (hydroxymethylated or negative control),
and 5 μM of each primer, with a total volume of 10 μl.
The 2.7 and 0.027 % of input PCR assays were completed
using the identical conditions, and input DNA stocks were
prepared at 33.3 and 0.33 ng/μl, respectively. All PCR as-
says included a non-template control, using UltraPure
Distilled Water (Invitrogen) as the template. The PCR
conditions were as follows: 30 s at 95 °C, 40 cycles of de-
naturation for 5 s at 95 °C, and annealing for 30 s at 60 °C.
Primers were designed using the specifications recom-
mended by Hydroxymethyl Collector protocol (Active
Motif) and targeted differentially hydroxymethylated re-
gions (DHMRs) identified by both hMeSeal-seq and
hMeDIP-seq. The sequences of primers amplifying: RAS-
GEF1a are 5′-GCA TGT TCC TTG AAC TGT GA-3′
(forward), 5′-TCA CAC CCT TCC CAA CAC TA-3′(re-
verse); HINT1 are 5′- CAT ATC CAA ATT GCC AGG
AT-3′ (forward), 5′- GCT GAC TTT GCT TTC AGA
CC-3′ (reverse); CUL2 are 5′-GGG GTG CAA TAT CTC
ACT GT-3′ (forward), 5′-GCT TGG AGA AGA CAC
ACA AA-3′ (reverse); and HOXD8 are 5′-AAC TTG
CGG TCG TCT GCC CT-3′ (forward), 5′-ACA GAA
ACG TTC TGA GGC GGG AAA-3′ (reverse). PCR reac-
tions were performed across three technical replicates.
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